| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/20/1993 | US5204098 Polysaccharide-protein conjugates |
| 04/20/1993 | US5204096 Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
| 04/20/1993 | CA1316524C Starburst conjugates |
| 04/20/1993 | CA1316458C Pharmaceutical composition for piperidinoalkanol derivatives |
| 04/20/1993 | CA1316456C Starburst conjugates |
| 04/20/1993 | CA1316364C Starburst conjugates |
| 04/16/1993 | CA2080574A1 Slow release syneresing polymeric drug delivery device |
| 04/16/1993 | CA2080502A1 Method for producing synthetic n-linked glycoconjugates |
| 04/16/1993 | CA2079830A1 Polymeric compositions useful as controlled release implants |
| 04/15/1993 | WO1993007291A1 Immunoglobulin d-associated glycans and uses thereof |
| 04/15/1993 | WO1993007283A1 Composition for inserting nucleic acid complexes into higher eucaryotic cells |
| 04/15/1993 | WO1993007282A1 New conjugates for the introduction of nucleic acid into higher eukaryotic cells |
| 04/15/1993 | WO1993007194A1 Thermoplastic elastomers |
| 04/15/1993 | WO1993006872A1 Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
| 04/15/1993 | WO1993006868A1 Dendrimeric polychelants |
| 04/15/1993 | WO1993006866A2 Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction |
| 04/15/1993 | WO1993006858A1 Lung cancer-associated protein |
| 04/15/1993 | WO1993006855A1 Hemostatic composition for local hemostasis |
| 04/15/1993 | WO1993006854A1 Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl |
| 04/15/1993 | WO1993006849A1 Binding of plasmodium falciparum-infected erythrocytes to cd36 |
| 04/15/1993 | WO1993006837A1 Process for preparing pvp-iodine product |
| 04/15/1993 | WO1993006824A1 Preparations containing transition-metal compounds for anti-tumour therapy and/or stimulating the haematopoietic system |
| 04/15/1993 | WO1993006812A2 Use of an emulsion to prepare an intravenously administered medicament for treating skin diseases |
| 04/15/1993 | DE4134158A1 Verwendung von wasser- oder lipidloeslichen uebergangsmetallverbindungen pharmazeutische zubereitungen und verfahren zur herstellung pharmazeutischer zubereitungen fuer die antitumortherapie und/oder stimulierung des haematopoetischen systems Use of water or lipidloeslichen by transition metal compounds pharmaceutical preparations and process for manufacture of pharmaceutical preparations for the antitumor therapy and / or stimulation of the hematopoietic system |
| 04/15/1993 | DE4133694A1 Verwendung einer emulsion, zur herstellung eines arzneimittels zur iv-verabreichung zur behandlung von hauterkrankungen Use of an emulsion, for the manufacture of a medicament for intravenous administration for the treatment of skin diseases |
| 04/15/1993 | CA2121028A1 Hemostatic composition for local hemostasis |
| 04/15/1993 | CA2120763A1 Dendrimeric polychelants |
| 04/15/1993 | CA2120755A1 Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl |
| 04/15/1993 | CA2120363A1 Lung cancer-associated protein |
| 04/15/1993 | CA2114800A1 New conjugates for the introduction of nucleic acid into higher eukaryotic cells |
| 04/14/1993 | EP0537070A1 Compositions containing compound TMK688 and its analogs |
| 04/14/1993 | EP0536595A1 Process for coating pharmaceutical preparations |
| 04/14/1993 | EP0536360A1 Topical treatment of acne |
| 04/14/1993 | EP0536343A1 Targeted polymeric conjugates of cyclosporin and method for their preparation. |
| 04/14/1993 | EP0536255A1 Ophthalmic suspensions. |
| 04/14/1993 | EP0536250A1 Aerosol drug formulations |
| 04/14/1993 | EP0536235A1 Pressurised aerosol compositions. |
| 04/14/1993 | EP0536211A1 Method of treatment and compositions therefore |
| 04/14/1993 | EP0536179A1 Bioceramic system for delivery of bioactive compounds |
| 04/14/1993 | EP0437478B1 Cyclodextrin-peptide complexes |
| 04/14/1993 | EP0349644B1 A method for the preparation of coated solid medicament form |
| 04/14/1993 | CN1070946A Composition for introducing nucleic acid complexes into higher eucaryotic cells |
| 04/13/1993 | US5202431 Partial esters of hyaluronic acid |
| 04/13/1993 | US5202352 Antitumor agents |
| 04/13/1993 | US5202311 Fibroblast growth factor stabilized with salt of sucrose octasulfate |
| 04/13/1993 | US5202252 Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction |
| 04/13/1993 | US5202159 Preparation method of microdispersed tablet formulation of spray-dried sodium diclofenac enteric-coated microcapsules |
| 04/13/1993 | US5202129 Process for micronizing slightly-soluble drug |
| 04/13/1993 | US5202125 Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes |
| 04/13/1993 | US5202116 Supression of cytokine-stimulated expression of MHC antigens |
| 04/13/1993 | US5202110 Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants |
| 04/13/1993 | CA1316110C Sustained release matrix formulations |
| 04/13/1993 | CA1316109C Sustained release drug preparation |
| 04/13/1993 | CA1316108C Formulation for preparing sustained release drugs for oral administration |
| 04/13/1993 | CA1316106C Skin permeation enhancer compositions using glycerol monolaurate |
| 04/09/1993 | CA2079938A1 Solid formulation containing amide derivative and method of manufacturing the formulation |
| 04/08/1993 | CA2079860A1 Coating of drug forms |
| 04/07/1993 | EP0535899A1 Injectable extended release formulations and methods |
| 04/07/1993 | EP0535827A1 Calcitonin suspensions for oral administration |
| 04/07/1993 | EP0535734A1 Long acting injectable formulations containing hydrogenated castor oil |
| 04/07/1993 | EP0535723A1 Buffered formulation of capitals |
| 04/07/1993 | EP0535704A1 Glycyrrhizin suppository |
| 04/07/1993 | EP0535576A1 New conjugates to introduce nucleic acid into higher eucaryotic cells |
| 04/07/1993 | EP0535534A1 Biocompatible emulsion particles |
| 04/07/1993 | EP0535327A1 Pharmaceutical composition containing felbinac |
| 04/07/1993 | EP0535237A1 Composition for relieving skin irritation and external preparation for percutaneous adminstration containing the same |
| 04/07/1993 | EP0535155A1 Libraries of modified peptides with protease resistance |
| 04/07/1993 | EP0535111A1 Transdermal administration of buprenorphine |
| 04/07/1993 | EP0535052A1 Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof |
| 04/06/1993 | US5200488 Polyorganosiloxane having a quaternary salt at its one terminal and percutaneous absorption-promoting agent |
| 04/06/1993 | US5200453 Preservative for ophthalmic solutions |
| 04/06/1993 | US5200430 Debridement of bodily cavities using debridement fluids |
| 04/06/1993 | US5200393 A lipid excipient of mono-oleoyl phosphatidylethanolamine (a lysophospholipid), a salt solution and a water soluble protein e.g. insulin |
| 04/06/1993 | US5200190 Estradiol dissolved in adhesive base: copolymer of 2-ethylhexyl acrylate and N-vinyl-2-pyrrolidone; flexible tape backing; impermeable to active ingredient |
| 04/06/1993 | US5200178 Method for tumor detection |
| 04/06/1993 | CA1315774C Anthraline-sterol complexes, their production process and their use as therapeutics and cosmetics |
| 04/06/1993 | CA1315692C Pharmaceutical compositions for topical application with systemic action |
| 04/06/1993 | CA1315684C Anti-retroviral agents and delivery system for the same |
| 04/06/1993 | CA1315682C Injection containing 3-benzoyloxy-1,3,5(10)-estratriene -17-¬4- p-(bis(2-chloroethyl)amino)phenyl -butanoyloxy| acetate as an active |
| 04/06/1993 | CA1315681C Tablet for use in the treatment of progesterone deficiency |
| 04/06/1993 | CA1315679C Rapidly dissoluble medicinal dosage unit and method of manufacture |
| 04/06/1993 | CA1315678C Alpha-tocopherol based vesicles |
| 04/05/1993 | WO1993006823A1 Verbenone, having antielastase activity, against pulmonary emphysema |
| 04/05/1993 | CA2097611A1 Verbenone, having antielastase actibity, against pulmonary emphysema |
| 04/03/1993 | CA2078388A1 Biocompatible emulsion particles |
| 04/02/1993 | CA2079541A1 Injectable extended release formulations and methods |
| 04/02/1993 | CA2079420A1 Pharmaceutical composition containing felbinac |
| 04/01/1993 | WO1993006231A1 Anti-human milk fat globule humanised antibodies |
| 04/01/1993 | WO1993006132A1 Modified peptide derivatives |
| 04/01/1993 | WO1993006075A1 Complex of compound having chalcone skeleton |
| 04/01/1993 | WO1993005819A1 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media |
| 04/01/1993 | WO1993005816A1 Compositions containing quinolone antibiotics and sulfonate of polystyrol |
| 04/01/1993 | WO1993005815A1 Synthetic transfection vectors |
| 04/01/1993 | WO1993005805A1 Emulsion containing parathyroid hormone for pernasal administration |
| 04/01/1993 | WO1993005804A1 Activated stromal fibroblast-specific antibody, f19 and methods of using the same |
| 04/01/1993 | WO1993005799A1 Lyophilized stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor |
| 04/01/1993 | WO1993005797A1 Compositions comprising a bactericidal/permeability increasing protein and a lipid carrier, methods of making same, and uses thereof |
| 04/01/1993 | WO1993005794A1 Preservative for pharmaceutical products |
| 04/01/1993 | WO1993005793A1 A novel conjugate, its preparation and use and a substrate prepared with the conjugate |
| 04/01/1993 | WO1993005787A1 Method of administering dipalmitoylphosphatidylcholine dispersions |